Adjuvant chemotherapy for early-stage non-small cell lung cancer: The past, the present and the future

Expert Opinion on Biological Therapy

Volumn 6, Issue 7, 2006, Pages 709-716

  Potti, Anil ^a   Ganti, Apar Kishor ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Early stage; Lung cancer; Outcome; Therapy

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXPERT WITNESS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EXPERT TESTIMONY; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS;

EID: 33746049470     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.7.709     Document Type: Review

References (51)

1. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56:106-130.
2. FELD R, RUBINSTEIN LV, WEISENBERGER TH: Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J. Clin. Oncol. (1984) 2:1352-1358.
3. IMMERMAN SC, VANECKO RM, FRY WA, HEAD LR, SHIELDS TW: Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann. Thorac. Surg. (1981) 32:23-27.
4. MOUNTAIN CF: A new international staging system for lung cancer. Chest (1986) 89(4 Suppl.):225S-233S.
5. HOLMES EC: Treatment of stage II lung cancer (T1N1 and T2N1). Surg. Clin. North Am. (1987) 67:945-949.
6. NARUKE T, GOYA T, TSUCHIYA R et al.: Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg. (1988) 96:440-447.
7. WILLIAMS DE, PAIROLERO PC, DAVIS CS et al.: Survival of patients surgically treated for stage I lung cancer. J. Thorac. Cardiovasc. Surg. (1981) 82:70-76.
8. SHIMIZU J, WATANABE Y, ODA M et al.: Results of surgical treatment of stage I lung cancer. Nippon Geka Gakkai Zasshi (J. Jpn. Surg. Soc.) (1993) 94:505-510.
9. MARTINI N, MCCAUGHAN BC, MCCORMICK P et al.: Lobectomy for Stage I lung cancer. In: Current Controversies in Thoracic Surgery. Kittle CF (Ed.), WB Saunders, Philadelphia, USA (1986):171-174.
10. SHAH R, SABANATHAN S, RICHARDSON J et al.: Results of surgical treatment of stage I and II lung cancer. J. Cardiovasc. Surg. (Torino) (1996) 37:169-172.
11. GIRLING DJ, STOTT H, STEPHENS RJ, FOX W: Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma. Br. J. Cancer (1985) 52:867-873. (Pubitemid 16229465)
12. SHIELDS TW, HUMPHREY EW, EASTRIDGE CE, KEEHN RJ: Adjuvant cancer chemotherapy after resection of carcinoma of the lung. Cancer (1977) 40:2057-2062. (Pubitemid 8239689)
13. SHIELDS TW, HIGGINS GA, HUMPHREY EW et al. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer (1982) 50:1713-1721.
14. FELD R, RUBINSTEIN L, THOMAS PA: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. The Lung Cancer Study Group. J. Natl Cancer Inst. (1993) 85:299-306.
15. NIIRANEN A, NIITAMO-KORHÔNEN S, KOURI M, ASSENDELFT A, MATTSON K, PYRHÔNEN S: Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J. Clin. Oncol. (1992) 10:1927-1932.
16. OHTA M, TSUCHIYA R, SHIMOYAMA M et al.: Adjuvant chemotherapy for completely resected stage III non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. (1993) 106:703-708.
17. HOLMES EC, GAIL M: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J. Clin. Oncol. (1986) 4:710-715.
18. NO AUTHORS LISTED: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br. Med. J. (1995) 311:899-909.
19. ARRIAGADA R, BERGMAN B, DUNANT A, LE CHEVALIER T, PIGNON JP, VANSTEENKISTE J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. International Adjuvant Lung Cancer Trial Collaborative Group. N. Engl. J. Med. (2004) 350:351-360.
20. WALLER D, FAIRLAMB DJ, GOWER N et al.: The Big Lung Trial: determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting. Proc. Am. Soc. Clin. Oncol. (2003) 22:632a.
21. SCAGLIOTTI GV, FOSSATI R, TORRI V et al.: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. J. Natl Cancer Inst. (2003) 95:1453-1461.
22. WINTON T, LIVINGSTON R, JOHNSON D et al.: Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. N. Engl. J. Med. (2005) 352:2589-2597.
23. STRAUSS GM, HERNDON J, MADDAUS MA et al.: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract). For CALGB, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group. Proc. Am. Soc. Clin. Oncol. (2004) 23:621s (Abstract #7019).
24. DOUILLARD J, ROSELL R, DELENA M, LEGROUMELLEC A, TORRES A, CARPAGNANO F: ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J. Clin. Oncol. (2005) 24:(Abstract #7013).
25. LE CHEVALIER T, BRISGAND D, DOUILLARD JY et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. (1994) 12:360-367.
26. GIACCONE G, SPLINTER TA, DEBRUYNE S et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (1998) 16:2133-2141.
27. BONOMI P, KIM K, FAIRCLOUGH D et al.: Comparison of survival and quality of life in non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. (2000) 18:623-631.
28. BELANI CP, LEE JS, SOCINSKI MA et al.: Randomized Phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann. Oncol. (2005) 16:1069-1075.
29. KELLY K, CROWLEY J, BUNN PA JR et al.: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. (2001) 19:3210-3218.
30. NO AUTHORS LISTED: Postoperative radiotherapy in non-small-cell lung cancer: systemic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet (1998) 352:257-262.
31. SEDRAKYAN A, VAN DER MEULEN J, O'BYRNE K, PRENDIVILLE J, HILL J, TREASURE T: Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Cardiovasc. Surg. (2004) 128:414-419.
32. NO AUTHORS LISTED: A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur. J. Surg. Oncol. (1995) 21:69-77.
33. FUKUSHIMA M, TSUSHIMA T, ITO H et al.: A randomized controlled study of post-operative adjuvant therapy in non-small cell lung cancer. Gan To Kagaku Ryoho (1996) 23:303-309. (Pubitemid 26062708)
34. WADA H, HITOMI S, TERAMATSU T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J. Clin. Oncol. (1996) 14:1048-1054.
35. WADA H, MIYAHARA R, TANAKA F, HITOMI S: Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur. J. Cardiothorac. Surg. (1999) 15:438-443.
36. ENDO C, SAITO Y, IWANAMI H et al.: A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer (2003) 40:181-186.
37. KATO H, ICHINOSE Y, OHTA M et al.: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. N. Engl. J. Med. (2004) 350:1713-1721.
38. NAKAGAWA M, TANAKA F, TSUBOTA N, OHTA M, TAKAO M, WADA H: A randomized Phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann. Oncol. (2005) 16:75-80.
39. HAMADA C, TANAKA F, OHTA M et al.: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:4999-5006.
40. NO AUTHORS LISTED: The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group. J. Clin. Oncol. (1988) 6:9-17.
41. DAUTZENBERG B, CHASTANG C, ARRIAGADA R et al.: Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer (1995) 76:779-786.
42. KELLER SM, ADAK S, WAGNER H et al.: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N. Engl. J. Med. (2000) 343:1217-1222.
43. HOTTA K, MATSUO K, UEOKA H, KIURA K, TABATA M, TANIMOTO M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:3852-3859.
44. HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE - A Phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2005) 23:5892-5899. (Pubitemid 46300205)
45. GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). For the TALENT Study Investigators. J. Clin. Oncol. (2004) 22:7010.
46. COHEN EE, HARAF DJ, STENSON KM et al.: Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial. J. Clin. Oncol. (2005) 23:(Abstract #5506).
47. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
48. LYNCH TJ, BELL D, HABER D et al.: Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. J. Clin. Oncol. (2005) 23:(Abstract #7006).
49. TSAO MS, SAKURADA A, LORIMER I et al.: Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. J. Clin. Oncol. (2005) 23:(Abstract #7007).
50. SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J. Clin. Oncol. (2005) 23:(Abstract #LBA4).
51. VAN DE VIJVER MJ, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347:1999-2009.